| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30022203 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022204 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022205 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022206 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022207 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022208 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022209 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022210 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022211 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022212 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | MTOR |
|---|---|
| DrugBank ID | DB00877 |
| Drug Name | Sirolimus |
| Target ID | BE0002386 |
| UniProt ID | P42345 |
| Regulation Type | inhibitor |
| PubMed IDs | 20005306; 19620795; 12742462; 11752352; 15365568; 33141044 |
| Citations | Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N: Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010 Mar;1804(3):433-9. doi: 10.1016/j.bbapap.2009.12.001. Epub 2009 Dec 11.@@Shuuin T, Karashima H: [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma]. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.@@Sehgal SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3 Suppl):7S-14S.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Chan S: Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004 Oct 18;91(8):1420-4.@@Ozates NP, Sogutlu F, Lerminoglu F, Demir B, Gunduz C, Shademan B, Avci CB: Effects of rapamycin and AZD3463 combination on apoptosis, autophagy, and cell cycle for resistance control in breast cancer. Life Sci. 2021 Jan 1;264:118643. doi: 10.1016/j.lfs.2020.118643. Epub 2020 Oct 24. |
| Groups | Approved; Investigational |
| Direct Classification | Macrolide lactams |
| SMILES | [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C(C)[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC |
| Pathways | |
| PharmGKB | PA451365 |
| ChEMBL | CHEMBL413 |
